The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Tag: Pancreatic Cancer
Hackensack Meridian Jersey Shore University Medical Center Welcomes Dr. Lee Peng as Chief of Gastroenterology
Hackensack Meridian Jersey Shore University Medical Center welcomed Lee F. Peng, M.D., PhD, as section chief of gastroenterology, department of medicine.
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
Researchers makes promising discoveries on role of vitamin B6 in pancreatic cancer
Vitamin B6 is beneficial in many ways, notably for its role in maintaining a strong immune system.
Age-Related Changes in Fibroblast Cells Promote Pancreatic Cancer Growth and Spread
Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.
UCLA-led research results in FDA approval of 4-drug combination for frontline treatment of metastatic pancreatic cancer
A four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and fluorouracil has been approved by the FDA for the first-line treatment of metastatic pancreatic adenocarcinoma.
Pancreatic cancer hijacks a brain-building protein
Scientists at Cold Spring Harbor Laboratory (CSHL) and the University of California, Davis have reached a new breakthrough in pancreatic cancer research—eight years in the making.
Expert from Rutgers Cancer Institute of New Jersey available for comment on FDA approval for NALIRIFOX: a new first-line treatment for patients with metastatic pancreatic cancer
On February 13, 2024, the Food and Drug Administration approved NALIRIFOX, a combonation chemotherapy, for the first-line treatment of metastatic pancreatic adenocarcinoma. Patrick Boland, MD, is a medical oncologist in the Gastrointestinal Oncology Program at Rutgers Cancer Institute of New…
MD Anderson Research Highlights for February 7, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
New Potential Immunotherapies for Pancreatic Cancer
Pancreatic cancer can be a devastating diagnosis due to its extremely aggressive nature and low survival rate.
High insulin levels directly linked to pancreatic cancer
First detailed explanation of why people with obesity and Type 2 diabetes are at an increased risk of pancreatic cancer
MD Anderson Research Highlights for October 25, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments at MD Anderson include positive results from a Phase I trial for patients with TP53-mutant acute myeloid leukemia, a novel machine learning platform to identify cancer biomarkers from liquid biopsies, a tumor-specific multi-microRNA delivery system to improve treatment outcomes in glioblastoma, a combination strategy to overcome treatment resistance in KRAS-mutated pancreatic cancer, and a new target for improving treatment response in patients with stomach cancer that has metastasized to the peritoneal cavity.
A Cancer Survival Calculator Is Being Developed Using Artificial Intelligence
Researchers have developed an artificial intelligence (AI)–based tool for estimating a newly diagnosed cancer patient’s chances for surviving long term, according to a study presented at the American College of Surgeons (ACS) Clinical Congress 2023.
New study suggests promising approach for treating pancreatic cancer
A new study carried out in mice, led by Queen Mary University of London, has identified cells that drive the spread of pancreatic cancer and discovered a weakness in these cells that could be targeted using existing drugs. This offers a promising new approach for treating pancreatic cancer.
Copycat nutrient leaves pancreatic tumors starving
A study led by scientists at Sanford Burnham Prebys suggests an entirely new approach to treat pancreatic cancer. The research shows that feeding tumors a copycat of an important nutrient starves them of the fuel they need to survive and grow.
Newfound mechanism suggests drug combination could starve pancreatic cancer
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.
Mayo Clinic’s AI innovation inspires hope in early detection of pancreatic cancer
Estimated to become the second leading cause of cancer deaths in the U.S. by 2030, pancreatic cancer has a grim prognosis with nearly 70% of patients facing mortality within the first year of diagnosis. Unfortunately, 40% of small pancreatic cancers elude detection on CT scans until they’ve advanced to an incurable stage.
The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research
The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research
US Department of Defense backs Cosimo Commisso’s pancreatic cancer research
Cosimo Commisso, Ph.D., has received a grant from the Department of Defense for $1 million to advance the research of a small molecule that kills pancreatic cancer cells by disrupting their pH equilibrium.
Pancreatic cancer research in vaccines, immune-based therapies and KRAS inhibition funded by The Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN), a leading non-profit in the fight against pancreatic cancer, has awarded Dana-Farber Cancer Institute researchers William Freed-Pastor, MD, PhD, and Julien Dilly, MS, research grants of $250,000 and $150,000, respectively over a 2-year period, to support their crucial work in the field of pancreatic cancer research.
Sylvester Surgeon-Scientist Awarded Center’s First Department of Defense Grant to Study Pancreatic Cancer
Researchers with Sylvester Comprehensive Cancer Center have been awarded a three-year, $800,000 grant from the U.S. Department of Defense (DoD)’s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer.
Sylvester Comprehensive Cancer Center Tip Sheet – August 2023
New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .
In battle against pancreatic cancer, grant-funded H-FIRE study offers hope
The National Institutes of Health has awarded $2.6 million to a Virginia Tech team over five years for a study of high frequency irreversible electroporation (H-FIRE) for tumor ablation and immune system activation in cases of pancreatic cancer.
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
Pancreatic Cancer Starts with Mutant Cells Affecting Ion Balance and Energy Production
Rockville, Md. (July 26, 2023)—Mutant cells that initially resemble normal enzyme-producing cells drive the development of pancreatic cancer, according to a new study in the journal Function. One key distinction is that mutant cells might show altered physiological characteristics early…
Pancreatic Cancer Risk Lower if Pancreatic Cysts Remain Stable for Five Years
Low-risk branch duct intraductal papillary mucinous neoplasms (IPMN) are the most common precancerous form of mucinous pancreatic cysts and once identified require regular surveillance imaging. But consensus is still forming around how long that watchful period should last.
Staging pancreatic cancer early with minimally invasive surgery shows positive results in patient prognosis, Mayo Clinic study finds
A study published in the Journal of the American College of Surgeons reveals that performing a minor surgical procedure on patients newly diagnosed with pancreatic cancer helps to identify cancer spread early and determine the stage of cancer.
One-Two Punch: Novel Drug Pairing Could Beat Pancreatic Cancer
UC San Diego researchers find a combination of drugs outperformed other treatments in human and mouse models of pancreatic cancer; now urge clinical trial.
UTHealth Houston study on repeated radiofrequency ablation in combination with chemotherapy for pancreatic cancer supported with $3.3M HHS grant
A combination strategy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with chemotherapy for pancreatic cancer will be studied at UTHealth Houston through a $3.3 million grant from the National Cancer Institute by the U.S. Department of Health and Human Services.
Implantable device shrinks pancreatic tumors
Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer – one of the most aggressive and difficult to treat cancers – by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice.
Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
UTEP to Investigate Pancreatic Cancer Risk Factors with $1M NIH Grant
The University of Texas at El Paso will undertake potentially transformative research on how specific risk factors promote pancreatic cancer development with support from a $1 million grant from the National Institutes of Health’s National Cancer Institute.
Sanford Burnham Prebys researchers awarded $2.6M to discover pancreatic cancer drugs
Cosimo Commisso, Ph.D., and Susanne Heynen-Genel, Ph.D., have received a grant from the National Cancer Institute (NCI) to advance a new treatment approach for pancreatic cancer.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
AI improving digestive cancer diagnosis, but data-sharing obstacles remain
Artificial intelligence is helping to deliver earlier and better diagnoses of digestive cancers, but many challenges remain to widespread clinical application, not least limited sharing of medical imaging data between hospitals, and lack of standardization of protocols for medical imaging for AI, a group of researchers has concluded after a comprehensive survey of recent applications of the technology to these most deadly of cancers.
Atlantic Health System’s Morristown Medical Center earns National Pancreas Foundation Center designation
Hospital joins only 160 other Centers of Excellence throughout the nation, designated as health care facilities that focus on multidisciplinary treatment of pancreas disease, treating the “whole patient” with a focus on the best possible outcomes and improved quality of life.
Mayo Clinic to lead new radiotracer trial for detecting pancreatic cancer
In an academic-industrial collaboration, Mayo Clinic is assessing in a clinical trial a new radiotracer in pancreatic cancer imaging.
Investigators’ Work to Outsmart Treatment Resistance in Pancreatic Cancer
A team of investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has shown for the first time that a combination of targeted therapies with immunotherapy addresses one of the major reasons pancreatic cancer…
Stress-Tolerant Cells Drive Tumor Initiation in Pancreatic Cancer
UC San Diego scientists discover a molecular pathway critical to the initiation of pancreatic tumors. The findings may inspire new chemotherapeutic drugs targeting early stages of tumor formation and spread.
Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic cancer.
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center.
Injectable, radioactive gel synergizes with chemotherapy to shrink pancreatic tumors
NIBIB-funded researchers are developing a new method to treat pancreatic cancer. In their study, they combined an injectable radioactive gel with systemic chemotherapy in multiple mouse models of the disease. The treatment resulted in tumor regression in all evaluated models, an unprecedented result for this genetically diverse and aggressive type of cancer.
New targets in the fight against pancreatic cancer
Pancreatic cancer remains one of the deadliest malignancies worldwide.
Study Shows Promising Safety, Patient Outcomes Data for MRI-Guided Adaptive Radiation Therapy to Treat Pancreatic Cancer
Findings from a recent prospective study show promising safety and patient outcomes data for locally advanced and borderline resectable pancreatic cancer treatment using ablative Stereotactic MRI-Guided On-table Adaptive Radiation Therapy, also known as SMART.
Stopping the Silent Killer – There’s New Hope for Early Stage Pancreatic Cancer
Imagine living with a ticking time bomb inside of you – never knowing when or if it might go off. “That’s what it’s like to know that you are at high risk for pancreatic cancer,” says a 40 year old…
Advances in treating pancreatic cancer mean options and hope
A diagnosis of cancer may feel devastating. And pancreatic cancer is the least survivable cancer of all known cancers. That’s because when it is diagnosed, it often has already spread. Mark Truty, M.D., a surgical oncologist at Mayo Clinic, says the stigma around the diagnosis can leave people feeling hopeless. He wants people with pancreatic cancer to know that advances in treatment mean more options are available than ever before.
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Two drugs reverse key pancreatic cancer step in the lab
Two drugs — one brand new — reverse pancreatic cell changes that presage one of the hardest cancers to treat. Tested in cells, the drugs would be a promising early cancer treatment if they work in clinical trials.
UCSF Surgeons Perform First Pure Robotic Whipple Surgery in the Bay Area
Gastrointestinal surgeons at UC San Francisco have performed the first pure robotically assisted Whipple surgery in San Francisco. The surgery was recently performed on a 77-year-old pancreatic cancer patient by surgeons Mohamed Adam, MD, and Adnan Alseidi, MD, MEd, FACS.